# RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

> **NCT04620733** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 193 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** Seladelpar 10 mg
- **DRUG:** Placebo
- **DRUG:** Seladelpar 5 mg

## Key facts

- **NCT ID:** NCT04620733
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-21
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-08-11
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620733, "RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04620733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*